• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Hepatitis C Virus NS4 a + b recombinant protein product blog

Tags: Recombinant Protein; Hepatitis C Virus NS4 a + b; Hepatitis C Virus NS4 a + b recombinant protein;

     The Hepatitis C Virus NS4 a + b n/a (Catalog #MBS537815) is a Recombinant Protein produced from Viral and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s Hepatitis C Virus NS4 a + b can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Western Blot (WB). Researchers should empirically determine the suitability of the Hepatitis C Virus NS4 a + b n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.

To buy or view more detailed product information and pricing, please click on the technical datasheet page below:


Our knowledge of the role of proteins in cellular processes is continually evolving. Most proteins, including Hepatitis C Virus NS4 a + b are typically involved in one or more signaling pathways or biological processes. Professionally manufactured recombinant proteins are increasingly becoming essential and commonplace tools for elucidating new knowledge about the role of proteins in both health and disease.

Hepatitis C Virus NS4 a + b n/a

Protein Type: Recombinant
Biological Significance: HCV is a small 50nm, enveloped, single-stranded, positive sense RNAvirus in the family Flaviviridae. HCV has a high rate of replication with approximately one trillion particles produced each day in an infected individual. Due to lack of proofreading by the HCV RNA polymerase, the HCV has an exceptionally high mutation rate, a factor that may help it elude the host\'s immune response. Hepatitis C virus is classified into six genotypes(1-6) with several subtypes within each genotype. The preponderance and distribution of HCV genotypes varies globally. Genotype is clinically important in determining potential response to interferon-based therapy and the required duration of such therapy. Genotypes 1 and 4 are less responsive to interferon-based treatment than are the other genotypes (2, 3, 5 and 6). Expression System: E Coli.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
1146 - Table 'mbsds_xtra.countries' doesn't exist

select countries_id, countries_name from countries order by countries_name

[TEP STOP]